A Phase III Trial of BMS-754807 in Combination With Trastuzumab Herceptin in Subjects With Advanced or Metastatic Her-2-positive Breast Cancer

Led by Bristol-Myers Squibb · Updated on 2012-07-13

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

This is a Phase I/II study to evaluate the safety profile, tolerability, pharmacokinetics and pharmacodynamics following daily oral doses of 50 to 200 mg of BMS-754807 in combination with trastuzumab (Herceptin®) in subjects with advanced or metastatic Her-2-positive breast cancer. In addition, the study is expected to identify the recommended dose or dose range of BMS-754807 in combination with trastuzumab for Phase II studies and provide preliminary evidence of anti-tumor activity in Her-2-positive breast cancer subjects after trastuzumab failure

CONDITIONS

Brief Title

Combination Study of BMS-754807 and Herceptin® in Patients With Advanced or Metastatic Her-2-positive Breast Cancer

Who Can Participate

Age: 18Years +

FEMALE

Eligibility Criteria

For additional information on this trial, please call (910) 558-2913

Inclusion Criteria:

Subjects with locally advanced or metastatic Her-2-positive breast cancer who have failed at least one trastuzumab containing regimen. Prior treatment with other Her-2-targeted agents (e.g. lapatinib, pertuzumab, trastuzumab DM-1 etc.) is allowed
Histologic or cytologic diagnosis of Her-2-positive breast cancer
ECOG status 0 - 1

Exclusion Criteria:

Symptomatic brain metastasis
Any condition requiring chronic use of steroids
Any disorder with dysregulation of glucose homeostasis (history of Type 1 or 2 Diabetes Mellitus or prediabetic symptoms
History of glucose intolerance
Women of child-bearing potential unwilling or unable to use acceptable contraception methods

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here